Pharma BD Deal Intelligence
A £1.9bn ($3.4bn) all-cash deal that made Nurofen and Strepsils durable, still-growing pillars of Reckitt's Health franchise two decades later, with Nurofen alone hitting an estimated £1.1bn in 2024 retail sales—though a mislabeling scandal over "Specific Pain" variants drew a record A$6 million Australian penalty in 2016.
Nurofen, Strepsils and Clearasil became durable pillars of Reckitt's Health franchise, though a high-profile Australian mislabeling scandal (2015-16) tarnished the Nurofen brand along the way.
Full analysis, sources & comparables →Reckitt outbid GSK and Bayer to win BHI for £1.9B; CEO Bart Becht said the deal would 'substantially strengthen' Reckitt's global position in healthcare and…
Reckitt would leverage its distribution network to push Nurofen, Strepsils and Clearasil into new channels and geographies; Boots CEO Richard Baker indicated…
Commission clearance decision: the operation does not create serious impediments to effective competition within the common market, permitting the Reckitt…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
OTC consumer health (Nurofen, Strepsils, Clearasil); GBP 1.93B
Nurofen, Strepsils and Clearasil became durable pillars of Reckitt's Health franchise, though a high-profile Australian mislabeling scandal (2015-16) tarnished the Nurofen brand along the way.
Assessment window: 15yr post-close.
This is a consumer OTC healthcare transaction rather than a therapeutic disease deal. Boots Healthcare International (BHI) marketed everyday self-care brands across analgesics (Nurofen ibuprofen), sore-throat lozenges (Strepsils), and acne care (Clearasil), serving general consumer self-medication needs across Europe, Asia and emerging markets.
BHI's portfolio competed in fragmented global OTC categories where the major rivals at the time of the deal were GlaxoSmithKline Consumer Healthcare (Panadol, Sensodyne), Johnson & Johnson (Tylenol, Motrin IB), Bayer Consumer Care (Aleve, Bayer Aspirin), Pfizer Consumer Healthcare (Advil) and Novartis OTC. Reckitt outbid both GSK and Bayer to win BHI, marking a deliberate pivot from cleaning-products dominance into branded healthcare. Per PharmaTimes, the deal was projected to lift combined H&PC revenue above £1B (~26% of the enlarged group, +90% growth) and the company guided to £75M cost synergies plus £130M working-capital synergies by 2008. Strategically, Nurofen gave Reckitt a #1 European ibuprofen brand to anchor distribution leverage, while Strepsils added the leading global sore-throat franchise and Clearasil extended into adolescent skincare. The deal repositioned Reckitt as the platform that would later acquire Adams Respiratory (Mucinex) in 2007 and Schiff Nutrition in 2012, building the Reckitt Health unit that today competes head-to-head with Haleon and Kenvue. Source: https://pharmatimes.com/news/reckitt_benckiser_buys_boots_otc_for_1-9bn_998907/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Reckitt Benckiser plc / Boots Healthcare International (this deal) | 2006 | $3.4B | 82 |
| Reckitt Benckiser plc / Adams Respiratory Therapeutics Inc. | 2007 | $2.3B | 82 |
| Reckitt Benckiser plc / Boots Healthcare International | 2005 | $3.4B | 78 |
| Reckitt Benckiser plc / Schiff Nutrition International, Inc. | 2012 | $1.4B | 67 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |